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Apophysomyces elegans is an emerging pathogen in India. We planned the present study to analyze the clinical
pattern of the disease, to perform molecular strain typing, and to determine the in vitro activities of eight
antifungal drugs against A. elegans. A total of 16 clinical and two environmental A. elegans isolates were
included in the study. The clinical histories of the patients were noted. MICs or minimum effective concen-
trations (MECs) were determined for antifungal drugs by microdilution testing in accordance with CLSI
standard M38-A2 guidelines. Of 16 patients, seven had rhino-cerebral, five had cutaneous, and three had renal
zygomycosis. One patient had osteomyelitis. Uncontrolled diabetes was observed in 63% of the patients.
Amplified fragment length polymorphism (AFLP) analysis divided the strains into two clearly different clades.
The fingerprints of the environmental strains (including the type strain) were clearly different from those of
the clinical strains. The MIC50s and MIC90s for amphotericin B, itraconazole, posaconazole, and isavuconazole
were 2 and 4, 1 and 2, 0.5 and 1, and 2 and 4 g/ml, respectively. The strains had high MICs for fluconazole,
voriconazole, and echinocandins. The study indicates a possible change in the clinical pattern of zygomycosis
due to A. elegans in India. The fungus caused not only cutaneous or subcutaneous infection but also other
deep-seated infections, and the disease is commonly associated with uncontrolled diabetes. The AFLP patterns
show a clear difference between environmental and clinical strains. Posaconazole is the most active drug
against the isolates, followed by itraconazole. The MICs of amphotericin B against A. elegans were higher than
those of the other drugs.
Zygomycosis (mucormycosis) is a serious and often rap-
idly fatal infection, especially in immunocompromised hosts.
Among zygomycetes, the species under the genera Rhizopus,
Rhizomucor, Lichtheimia (Absidia), Mucor, Apophysomyces,
Saksenaea, Cunninghamella, Cokeromyces, and Syncephalas-
trum have been reported to cause invasive zygomycosis, and
the species under Rhizopus, Lichtheimia, and Rhizomucor are
the more commonly reported pathogens (5, 25, 32, 33). How-
ever, Apophysomyces elegans, once considered a rare pathogen,
has increasingly been isolated from patients in tropical and
subtropical climates over the last 2 decades (5, 25, 32). Patients
with A. elegans infection have been documented from India,
the southern United States, Australia, Mexico, Caribbean is-
lands, Colombia, and Venezuela. However, of nearly 100 cases
published in the literature, the majority (60%) were from
India (5–7, 12, 17, 25, 32, 38). A. elegans was believed to cause
only cutaneous and mucocutaneous infection in immunocom-
petent hosts, but it has been implicated in serious deep-seated
infections (rhino-orbito-cerebral and renal zygomycosis) in re-
cent years (5–8, 22, 23, 32, 35). Wound contamination with soil
(possibly harboring A. elegans spores) after an accident is con-
sidered the single most important risk factor for cutaneous or
subcutaneous zygomycosis due to A. elegans (25, 32). However,
it is not clear how A. elegans acquisition occurs in patients with
rhino-cerebral or renal zygomycosis. To understand the epide-
miology of the disease, molecular strain typing is important.
No serious attempt has been made to perform strain typing of
A. elegans except our previous attempt to type the strains using
two microsatellites (7).
As with other cases of zygomycosis, amphotericin B and its
lipid formulations have been the mainstay of therapy in pa-
tients with A. elegans infections (32, 33), though there contin-
ues to be a need for developing new treatment strategies due
to the limitations of amphotericin B caused by its toxicity. In
search of an alternative therapy, in vitro antifungal susceptibil-
ity testing was performed for large collections of zygomycetes.
The results showed that the zygomycetes consist of a hetero-
geneous group with differing antifungal susceptibilities (1, 2, 4,
10, 21, 30, 34). However, it is difficult to comment on A.
elegans, as only 11 isolates have been subjected to in vitro
antifungal susceptibility testing to date, and they were tested
against a limited number of antifungal agents (2, 10, 34).
Therefore, to address both problems, we evaluated the in vitro
activities of eight antifungal agents, including isavuconazole, a
new triazole drug, against 18 A. elegans strains and typed those
A. elegans strains by amplified fragment length polymorphism
(AFLP) analysis.
* Corresponding author. Mailing address: Department of Medical
Microbiology, Post graduate Institute of Medical Education and Re-
search, Chandigarh 160012, India. Phone: 91 172 2747990. Fax: 91 172
2744401. E-mail: Arunaloke@hotmail.com.
 Published ahead of print on 29 September 2010.
4580
 o
n
 M
ay 1, 2017 by RADBO
UD UNIVERSITEIT NIJM
EG
EN
http://jcm.asm.org/
D
ow
nloaded from
 
MATERIALS AND METHODS
Apophysomyces elegans isolates. A total of 18 A. elegans isolates were used in
the present study. A collection of 15 clinical isolates were obtained from the
National Culture Collection of Pathogenic Fungi, Chandigarh, India, and three
strains were obtained from the Centraalbureau voor Schimmelcultures (CBS)
Fungal Biodiversity Centre, Utrecht, Netherlands (two environmental isolates,
CBS 476.78 and CBS 477.78, and one clinical isolate, CBS 658.93). The identity
of each isolate was verified based on taxonomic criteria by conventional proce-
dures (16) and then confirmed by DNA sequencing of internal transcribed spacer
regions (ITS1 and -2) and the 5.8S region. The clinical details of the 16 patients
from whom the isolates were obtained are presented in Table 1.
Antifungals tested. Antifungals used in this study included amphotericin B
(AMB; Bristol Myers Squibb, Woerden, Netherlands), itraconazole (ITR; Jans-
sen Cilag, Tilburg, Netherlands), fluconazole and voriconazole (FLU and VOR,
respectively; Pfizer Central Research, Kent, United Kingdom), posaconazole
(POS; Schering-Plough Corp., Kenilworth, NJ), isavuconazole (ISA; Basilea
Pharmaceutica, Basel, Switzerland), caspofungin (CAS; Merck Sharp & Dohme
BV, Haarlem, Netherlands), and anidulafungin (ANI; Pfizer Central Research).
Antifungal susceptibility testing. The MICs or minimum effective concentra-
tions (MECs) (for CAS and ANI) were determined by the broth microdilution
method, in accordance with the guidelines of CLSI document M38-A2 (9). Stock
solutions (3,200 mg/liter) of AMB, ISA, ITR, POS, and VOR were prepared
using dimethyl sulfoxide solution (DMSO), while FLU, CAS, and ANI were
dissolved in sterile distilled water to a final stock concentration of 3,200 mg/liter.
Final concentrations for each antifungal solution were made using filter-steril-
ized (0.22-m filter) RPMI 1640 medium with L-glutamine (Difco, Breda, Neth-
erlands). Growth was assessed visually after incubation in ambient air at 35°C for
24 h. To induce sporulation, we used a previously reported method (27). Two
1-cm2 agar blocks with hyphal growth on Sabouraud dextrose agar were cut and
transferred to a petri dish containing 20 ml of sterile distilled water. Three drops
(0.2 ml) of a filter-sterilized 10% yeast extract solution were added to each plate.
The plates were incubated in the dark at 35°C. After 5 days of incubation,
sporulation appeared. The spore concentrations were adjusted spectrophoto-
metrically at a 530-nm wavelength to a transmission that ranged from 68 to 71%
(0.6  106 to 4  106 CFU/ml). MICs for AMB and the azoles corresponded to
a 100% reduction in growth relative to that of control wells lacking an antifungal.
MECs for CAS and ANI, assessed microscopically, corresponded to the lowest
drug concentration at which abnormal hyphae were observed at 24 h of incuba-
tion. Paecilomyces variotii (ATCC 22319) and Candida krusei (ATCC 6258) were
included in the study as quality control strains. Values for MIC50 and MIC90
were obtained by ordering the MIC data for each antifungal in ascending arrays
and selecting the median and 90th percentile, respectively, of the MIC distribu-
tion.
AFLP analysis. Approximately 50 ng of genomic DNA was subjected to a
combined restriction-ligation procedure with a mixture containing 50 pmol of the
HpyCH4 IV adapter, 50 pmol of the MseI adapter, 2 U of HpyCH4 IV (New
England Biolabs, Beverly, MA), 2 U of MseI (New England Biolabs), and 1 U of
T4 DNA ligase (Promega, Leiden, Netherlands) in a total volume of 20 l of 1
reaction buffer for 1 h at 20°C. Next, the mixture was diluted five times with 10
mM Tris-HCl (pH 8.3) buffer. Adapters were made by mixing equimolar
amounts of complementary oligonucleotides (5-CTCGTAGACTGCGTACC-3
and 5-CGGGTACGCAGTC-3 for HpyCH4 IV; 5-GACGATGAGTCCTGA
C-3 and 5-TAGTCAGGACTCAT-3 for MseI) and heating them to 95°C for
2 min, with subsequent slow cooling to ambient temperature. One microliter of
the diluted restriction-ligation mixture was used for amplification in a volume of
25 l under the following conditions: 1 M HpyCH4 IV primer with one selec-
tive residue (underlined) (5-fluorescent-GTAGACTGCGTACCCGTA-3), 1
M MseI primer with four selective residues (5-GATGAGTCCTGACTAATG
AG-3), 0.2 mM each deoxynucleoside triphosphate (dNTP), and 1 U of Taq
DNA polymerase (Roche Diagnostics) in 1 reaction buffer containing 1.5 mM
MgCl2. Amplification was performed as follows. After an initial denaturation
step for 4 min at 94°C, we applied to the first 20 cycles a touchdown procedure
consisting of 15 s of denaturation at 94°C and 15 s of annealing at 66°C, with the
temperature for each successive cycle lowered by 0.5°C, followed by 1 min of
extension at 72°C. Cycling was then continued for a further 30 cycles, with an
annealing temperature of 56°C. After completion of the cycles, incubation at
72°C for 10 min was performed before the reaction mixtures were cooled to room
temperature. Reaction products were diluted 10-fold with distilled water. One
microliter of diluted products was combined with 0.25 l of the ET400-R size
marker (GE Healthcare, Diegem, Belgium) and 8.75 l of distilled water. After
a 1-min denaturation step at 94°C, the samples were quickly cooled to room
temperature and injected onto a MegaBACE 500 automated DNA analysis
platform equipped with a 48-capillary array, as recommended by the manu-
facturer (GE Healthcare). Typing data were imported into BioNumerics v5.0
software (Applied Maths, Sint-Martens-Latem, Belgium) and analyzed by
using clustering by the unweighted-pair group method using average linkages
(UPGMA) and the Pearson correlation coefficient.
RESULTS
The details of the 16 patients (including demography, site of
infection, risk factors, therapy, and outcome) and the sources
of the two environmental strains are presented in Table 1. All
patients were from India except one (case 16) (Table 1), who
was from the Caribbean. It is of interest to note that of the 16
patients, seven patients had rhino-cerebral, five had cutaneous,
and three had renal zygomycosis. In one patient, A. elegans was
isolated from bone tissue, which was reported earlier (26).
Uncontrolled diabetes was a risk factor in 10 patients, intra-
muscular injection in two patients (one with diabetes mellitus),
and application of occlusive plaster in one patient; no risk
factors could be ascertained in three patients. All patients
except one (who expired before surgery could be performed)
had extensive debridement or surgery to remove necrotic
masses or the affected kidney. Amphotericin B deoxycholate
was prescribed for the majority (75%) of patients; one patient
received a lipid formulation of amphotericin B, one patient
received three antifungal drugs (at first, amphotericin B, and
then itraconazole after development of toxicity because of am-
photericin B, followed by posaconazole), one patient had flu-
conazole (the patient had associated invasive candidiasis), and
the other two patients expired before institution of any anti-
fungal agent. In the outcome analysis, 40% of the patients with
a known course of disease had a fatal outcome. The outcome
was poorer (67% fatality) in patients with rhino-orbito-cere-
bral zygomycosis.
The detailed results of in vitro susceptibility testing against
each antifungal agent are presented along with the isolates in
Table 1. Summaries of the results in the form of MIC/MEC
range, geometric mean MIC/MEC50, and MIC/MEC90 are tab-
ulated and compared with those from previously published
series (2, 10, 34) in Table 2. The strains in the present series
had high MICs of fluconazole, voriconazole, and the two echi-
nocandins. The MIC50 and MIC90 of amphotericin B for the
strains were 2 and 4 g/ml; and the MIC50 and MIC90 results
for itraconazole, posaconazole, and isavuconazole were 1 and
2, 0.5 and 1, and 2 and 4 g/ml, respectively. The single patient
who developed infection due to an A. elegans strain with a MIC
of1 g/ml for amphotericin had a positive outcome, whereas
of those patients infected with strains with MICs of 1 g/ml,
43% had a poor outcome.
The AFLP fingerprints obtained with MseI and HpyCH4 IV
contained multiple bands in the range of 50 to 250 bp (Fig. 1).
The dendrogram yielded a clear separation between clinical
and environmental isolates. The clinical isolates had an aver-
age similarity of greater than 90%. The two environmental
isolates (CBS 476.78 and CBS 477.78) were 95% similar, but
they were less than 20% similar to the clinical isolates. A
clinical isolate from the Caribbean was clustered in the same
clade as the clinical isolates from India. One other sample
(102.37) yielded a faint fingerprint but still clustered well
within the remainder of the isolates.
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DISCUSSION
A. elegans in tropical and subtropical countries has been
described as an emerging pathogen, known to cause cutaneous
infection after traumatic inoculation (5–8, 12, 17, 22, 25, 28, 32,
33, 35, 38). However, in the present series, only 31% of pa-
tients had cutaneous infection, in comparison to 44% of pa-
tients with rhino-cerebral involvement. The third (19%) com-
mon presentation was renal zygomycosis. Further, it has been
assumed that the majority of patients with A. elegans infection
demonstrate no underlying immune dysfunction. Only a few
patients have been reported with risk factors like diabetes,
severe burns, renal transplantation, myelofibrosis, and cortico-
steroid use (5, 32). However, among our patients, 63% had
uncontrolled diabetes as a risk factor. All these patients except
one were diagnosed in India from 2004 through 2008. The
epidemiology of zygomycosis in India has been observed to be
different from that of developed countries (25). A phenomenal
increase in the number of cases of zygomycosis has been re-
ported from this country in patients with uncontrolled diabetes
(5, 6). The number of cases with uncontrolled diabetes is so
overwhelming that other factors are overshadowed (25). It
seems that the epidemiology of A. elegans infections in India is
also different from that in other countries. A. elegans is re-
ported to produce rhino-cerebral and renal zygomycosis in a
considerable number of patients, and uncontrolled diabetes is
strongly associated with such patients. In cutaneous A. elegans
infection, local wound contamination after an accident or in-
jury represents the common method of spread of the disease
(25), but it is not clear how the acquisition of A. elegans occurs
in patients with rhino-cerebral or renal zygomycosis. In a re-
view of seven cases of rhino-cerebral zygomycosis due to A.
elegans, three patients had predisposing facial or head trauma,
but the majority had no predisposing condition. As with other
zygomycetes, the infection may be acquired in those patients
via inhalation of spores (22). Similarly, in the cases with pri-
mary renal zygomycosis due to A. elegans, the lung was the
possible route of entry.
AFLP analysis, a high-resolution robust fingerprinting assay,
TABLE 2. Comparison of in vitro susceptibility patterns of
A. elegans strains reported in different seriesa
Drug and
parameters
Result reported byb:
Almyroudis et
al. (2) (6
strains)
Sun et al. (34)
(4 strains)
Dannaoui et
al. (10) (1
strain)
Present
study (18
strains)
Amphotericin B
Range 0.03–1 0.03–1 2 0.25–4
MIC50 0.125 0.03 2 2
MIC90 NA 0.25 2 4
Fluconazole
Range 64 64 4–64
MIC50 64 64 64
MIC90 64 64 64
Itraconazole
Range 0.03–4 0.03–8 0.5 0.25–2
MIC50 0.125 0.5 NA 1
MIC90 NA 2 NA 2
Voriconazole
Range 0.125 16–64 16 2–16
MIC50 NA 32 NA 16
MIC90 NA 64 NA 16
Posaconazole
Range 0.016–1 0.03–4 0.5 0.125–1
MIC50 0.03 0.25 NA 0.5
MIC90 NA 2 NA 1
Isavuconazole
Range 1–4
MIC50 2
MIC90 4
Caspofungin
Range 16 0.5–16
MEC50 NA 16
MEC90 NA 16
Anidulafungin
Range 0.008–8
MEC50 8
MEC90 8
a NA, not available; MEC, minimum effective concentration.
b Values are in micrograms per milliliter.
FIG. 1. AFLPs of 18 Apophysomyces isolates. Only bands in the range of 50 to 250 bp are shown. The scale bar indicates the percentages of
similarity. Except for the CBS (Centraalbureau voor Schimmelcultures) numbers, all numbers next to the lanes correspond to the NCCPF
(National Culture Collection of Pathogenic Fungi) collection.
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is a promising tool for strain typing of fungi (19). The tech-
nique not only has high sensitivity, reproducibility, and reso-
lution but also has the ability to amplify between 50 and 100
fragments from random locations scattered throughout the
genome, with no prior sequence information needed. The
technique has been used to type Candida and Aspergillus spe-
cies (11, 19) but has never been used to type zygomycetes,
including A. elegans. Fingerprinting using two microsatellite
markers was used to type A. elegans strains with limited success
(7). In the present study, AFLP typing was used to estimate the
extent of genetic diversity among A. elegans isolates and to
determine any specific genotypes associated with specific clin-
ical types of the disease. AFLP analysis revealed that most of
the isolates had very similar fingerprints with relatively little
genomic variation. However, based on the presence or absence
of variable bands in the AFLP fingerprints, the majority of
clinical isolates were grouped into a single clade. The genetic
variability was observed among the isolates regardless of their
clinical types or the year of isolation. Interestingly, the banding
patterns of the environmental isolates were found to be clearly
different from those of the clinical isolates. AFLP analysis has
been shown to be useful not only for strain typing but also as
a powerful tool to distinguish between closely related fungal
species (19). Therefore, our results question the homogeneity
of A. elegans species. Recently, Alvarez et al. also suggested
heterogeneity in the strains of A. elegans after sequencing the
histone 3 gene, the internal transcribed spacer region of ribo-
somal DNA (rDNA), and domains D1 and D2 of the 28S
rRNA gene (3). Therefore, it would be pertinent to analyze
larger collections of A. elegans strains to understand their tax-
onomic position and molecular epidemiology.
Amphotericin B is the most commonly used drug in patients
with zygomycosis, and it also shows the best in vitro activity
against the majority of zygomycetes. However, variation in
susceptibility among strains under each species is observed (1,
2, 4, 10, 21, 23, 30, 34). In the two reported series where limited
strains of A. elegans were tested (2, 34), the MIC50s of ampho-
tericin were 0.03 to 0.125 g/ml (Table 2). However, our
strains were comparatively more resistant, as the MIC50 and
MIC90 were 2 and 4 g/ml, respectively. The methods of in
vitro susceptibility testing might have some bearing on the
difference, as we used RPMI 1640, in contrast to antibiotic
medium 3 (Difco), which was used by the other two studies (2,
33). However, a correlation was observed in our in vitro sus-
ceptibility results with our in vivo outcome analysis, as the
patient having a strain with a MIC of 1 g/ml for amphoter-
icin B recovered, whereas 43% of the patients infected with
strains having MICs of 1 g/ml succumbed to their illnesses.
Still, with our study being retrospective, it may not be ideal for
in vitro and in vivo correlations.
Although itraconazole is not preferred as a zygomycete-
active compound, the in vitro susceptibility data show that
itraconazole is reasonably active against zygomycetes (1, 2, 18,
20, 21, 34). Even some cases of zygomycosis were treated
successfully with itraconazole (13, 29). After the in vitro sus-
ceptibility testing results of itraconazole against A. elegans were
analyzed, it appears that itraconazole may be useful in patients
infected with a susceptible strain.
Posaconazole is the first drug among azoles demonstrating
good antizygomycete activity, with a MIC50 of 1 g/ml (1, 2,
10, 34). A similar observation was made for this collection of A.
elegans isolates (Table 2). The drug has been recommended as
salvage therapy in patients with zygomycosis (13, 36) and has
also been used to treat patients with A. elegans infection (14,
28). A patient with complicated rhino-orbital A. elegans zygo-
mycosis was successfully treated with posaconazole after fail-
ure of liposomal amphotericin B therapy (14). However, fail-
ure after posaconazole therapy was also noted in a patient with
a brain abscess due to A. elegans and a basidiomycete species
(31). Isavuconazole demonstrated potent in vitro activity
against Aspergillus sp. (15, 24) and limited antifungal activity
against zygomycetes (15, 24, 30, 37). In comparison to the
results with itraconazole, ravuconazole, and voriconazole, isa-
vuconazole showed potent activity against zygomycetes, espe-
cially against Rhizopus species (15, 30, 37). The drug was never
evaluated against A. elegans strains. In the present study, the
MIC50 for isavuconazole was 2 g/ml. Therefore, the drug may
be an alternative treatment for A. elegans infection.
The study confirms the emerging trend of invasive zygomy-
cosis due to A. elegans. The fungus caused not only cutaneous
or subcutaneous infection but also rhino-orbito-cerebral and
renal zygomycosis. Uncontrolled diabetes is strongly associated
with the disease. The AFLP pattern raises serious doubt about
the homogeneity of A. elegans species. In vitro susceptibility
testing demonstrates similar susceptibility patterns, as in other
zygomycetes. Increased MICs of amphotericin B were ob-
served in the majority of strains. Posaconazole is a promising
drug to treat such patients, and isavuconazole or itraconazole
are possible alternatives in patients having infection due to
susceptible strains.
ACKNOWLEDGMENTS
We thank Hamid Badali for his help with part of the susceptibility
testing and Corina Bens for technical support.
This study was partly supported by an educational grant from
Basilea Pharmaceuticals International (Basel, Switzerland).
J.F.M. has been a consultant to Astellas, Basilea, Merck, and Scher-
ing-Plough and received speaker’s fees from Gilead, Janssen Pharma-
ceutica, Merck, Pfizer, and Schering-Plough. No other authors have
potential conflicts of interest.
REFERENCES
1. Alastruey-Izquierdo, A., M. V. Castelli, I. Cuesta, O. Zaragoza, A. Monzon,
E. Mellado, and J. L. Rodriguez-Tudela. 2009. In vitro activity of antifungals
against Zygomycetes. Clin. Microbiol. Infect. 15(Suppl. 5):71–76.
2. Almyroudis, N. G., D. A. Sutton, A. W. Fothergill, M. G. Rinaldi, and S.
Kusne. 2007. In vitro susceptibilities of 217 clinical isolates of zygomycetes to
conventional and new antifungal agents. Antimicrob. Agents Chemother.
51:2587–2590.
3. Alvarez, E., A. M. Stchigel, J. Cano, D. A. Sutton, A. W. Fothergill,
J. Chander, V. Salas, M. G. Rinaldi, and J. Guarro. 2010. Molecular phy-
logenetic diversity of the emerging mucoralean fungus Apophysomyces: pro-
posal of three new species. Rev. Iberoam. Micol. 27:80–89.
4. Antachopoulos, C., J. Meletiadis, E. Roilides, T. Sein, and T. J. Walsh. 2006.
Rapid susceptibility testing of medically important zygomycetes by XTT
assay. J. Clin. Microbiol. 44:553–560.
5. Chakrabarti, A., S. S. Chatterjee, A. Das, N. Panda, M. R. Shivaprakash, A.
Kaur, S. C. Varma, S. Singhi, A. Bhansali, and V. Sakhuja. 2009. Invasive
zygomycosis in India: experience in a tertiary care hospital. Postgrad. Med.
J. 85:573–581.
6. Chakrabarti, A., A. Das, J. Mandal, M. R. Shivaprakash, V. K. George, B.
Tarai, P. Rao, N. Panda, S. C. Verma, and V. Sakhuja. 2006. The rising trend
of invasive zygomycosis in patients with uncontrolled diabetes mellitus. Med.
Mycol. 44:335–342.
7. Chakrabarti, A., A. Ghosh, G. S. Prasad, J. K. David, S. Gupta, A. Das, V.
Sakhuja, N. K. Panda, S. K. Singh, S. Das, and T. Chakrabarti. 2003.
Apophysomyces elegans: an emerging zygomycete in India. J. Clin. Microbiol.
41:783–788.
4584 CHAKRABARTI ET AL. J. CLIN. MICROBIOL.
 o
n
 M
ay 1, 2017 by RADBO
UD UNIVERSITEIT NIJM
EG
EN
http://jcm.asm.org/
D
ow
nloaded from
 
8. Chakrabarti, A., N. Panda, S. C. Varma, K. Singh, A. Das, S. C. Sharma, and
A. A. Padhye. 1997. Craniofacial zygomycosis caused by Apophysomyces
elegans. Mycoses 40:419–421.
9. Clinical and Laboratory Standards Institute. 2008. Reference method for
broth dilution antifungal susceptibility testing of filamentous fungi. Ap-
proved standard M38-A2. Clinical and Laboratory Standards Institute,
Wayne, PA.
10. Dannaoui, E., J. Meletiadis, J. W. Mouton, J. F. Meis, and P. E. Verweij.
2003. In vitro susceptibilities of zygomycetes to conventional and new anti-
fungals. J. Antimicrob. Chemother. 51:45–52.
11. Dassanayake, R. S., and L. P. Samaranayake. 2003. Amplification-based
nucleic acid scanning techniques to assess genetic polymorphism in Candida.
Crit. Rev. Microbiol. 29:1–24.
12. Devi, S. C., R. Kanungo, E. Barreto, A. G. Thomas, N. Shashikala, S.
Srinivasan, and P. K. Anitha. 2008. Favorable outcome of amphotericin B
treatment of zygomycotic necrotizing fascitis caused by Apophysomyces el-
egans. Int. J. Dermatol. 47:407–409.
13. Eisen, D. P., and J. Robson. 2004. Complete resolution of pulmonary Rhi-
zopus oryzae infection with itraconazole treatment: more evidence of the
utility of azoles for zygomycosis. Mycoses 47:159–162.
14. Ferguson, T. D., S. D. Schniederjan, J. Dionne-Odom, M. E. Brandt, M. G.
Rinaldi, F. S. Nolte, A. Langston, and S. M. Zimmer. 2007. Posaconazole
treatment for Apophysomyces elegans rhino-orbital zygomycosis following
trauma for a male with well-controlled diabetes. J. Clin. Microbiol. 45:1648–
1651.
15. Guinea, J., T. Pelaez, S. Recio, M. Torres-Narbona, and E. Bouza. 2008. In
vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and
fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusar-
ium, and Scedosporium species. Antimicrob. Agents Chemother. 52:1396–
1400.
16. Hoog, G. S., J. Guarro, J. Gene´, and M. J. Figueras. 2000. Atlas of clinical
fungi, 2nd ed. Centraalbureau voor Schimmelcultures, Utrecht, Netherlands.
17. Jain, D., Y. Kumar, R. K. Vasishta, L. Rajesh, S. K. Pattari, and A.
Chakrabarti. 2006. Zygomycotic necrotizing fasciitis in immunocompetent
patients: a series of 18 cases. Mod. Pathol. 19:1221–1226.
18. Johnson, E. M., A. Szekely, and D. W. Warnock. 1998. In vitro activity of
voriconazole, itraconazole and amphotericin B against filamentous fungi. J.
Antimicrob. Chemother. 42:741–745.
19. Klaassen, C. H., and N. Osherov. 2007. Aspergillus strain typing in the
genomics era. Stud. Mycol. 59:47–51.
20. Kondori, N., E. Svensson, and I. Mattsby-Baltzer. 2010. In vitro susceptibility
of filamentous fungi to itraconazole, voriconazole and posaconazole by Clin-
ical and Laboratory Standards Institute reference method and E-test. My-
coses doi:10.1111/j.1439-0507.2010.01913.x.
21. Lass-Florl, C., A. Mayr, S. Perkhofer, G. Hinterberger, J. Hausdorfer, C.
Speth, and M. Fille. 2008. Activities of antifungal agents against yeasts
and filamentous fungi: assessment according to the methodology of the
European Committee on Antimicrobial Susceptibility Testing. Antimi-
crob. Agents Chemother. 52:3637–3641.
22. Liang, K. P., I. M. Tleyjeh, W. R. Wilson, G. D. Roberts, and Z. Temesgen.
2006. Rhino-orbitocerebral mucormycosis caused by Apophysomyces elegans.
J. Clin. Microbiol. 44:892–898.
23. Marak, R. S., R. Misra, M. S. Ansari, A. Dixit, Poornima, K. N. Prasad, and
T. N. Dhole. 1 April 2010. Successful medical management of renal zygomy-
cosis: a summary of two cases and a review of the Indian literature. Med.
Mycol. [Epub ahead of print.] doi:10.3109/13693781003753477.
24. Martin de la Escalera, C., A. I. Aller, E. Lopez-Oviedo, A. Romero, A. I.
Martos, E. Canton, J. Peman, P. Garcia Martos, and E. Martin-Mazuelos.
2008. Activity of BAL 4815 against filamentous fungi. J. Antimicrob. Che-
mother. 61:1083–1086.
25. Meis, J. F., and A. Chakrabarti. 2009. Changing epidemiology of an emerg-
ing infection: zygomycosis. Clin. Microbiol. Infect. 15(Suppl. 5):10–14.
26. Meis, J. F., B. J. Kullberg, M. Pruszczynski, and R. P. Veth. 1994. Severe
osteomyelitis due to the zygomycete Apophysomyces elegans. J. Clin. Micro-
biol. 32:3078–3081.
27. Padhye, A. A., and L. Ajello. 1988. Simple method of inducing sporulation by
Apophysomyces elegans and Saksenaea vasiformis. J. Clin. Microbiol. 26:
1861–1863.
28. Page, R. L., J. Schwiesow, and A. Hilts. 2007. Posaconazole as salvage
therapy in a patient with disseminated zygomycosis: case report and review
of the literature. Pharmacotherapy 27:290–298.
29. Parthiban, K., S. Gnanaguruvelan, C. Janaki, G. Sentamilselvi, and J. M.
Boopalraj. 1998. Rhinocerebral zygomycosis. Mycoses 41:51–53.
30. Perkhofer, S., V. Lechner, and C. Lass-Florl. 2009. In vitro activity of isa-
vuconazole against Aspergillus species and zygomycetes according to the
methodology of the European Committee on Antimicrobial Susceptibility
Testing. Antimicrob. Agents Chemother. 53:1645–1647.
31. Pitisuttithum, P., R. Negroni, J. R. Graybill, B. Bustamante, P. Pappas, S.
Chapman, R. S. Hare, and C. J. Hardalo. 2005. Activity of posaconazole in
the treatment of central nervous system fungal infections. J. Antimicrob.
Chemother. 56:745–755.
32. Ribes, J. A., C. L. Vanover-Sams, and D. J. Baker. 2000. Zygomycetes in
human disease. Clin. Microbiol. Rev. 13:236–301.
33. Roden, M. M., T. E. Zaoutis, W. L. Buchanan, T. A. Knudsen, T. A.
Sarkisova, R. L. Schaufele, M. Sein, T. Sein, C. C. Chiou, J. H. Chu, D. P.
Kontoyiannis, and T. J. Walsh. 2005. Epidemiology and outcome of zygo-
mycosis: a review of 929 reported cases. Clin. Infect. Dis. 41:634–653.
34. Sun, Q. N., A. W. Fothergill, D. I. McCarthy, M. G. Rinaldi, and J. R.
Graybill. 2002. In vitro activities of posaconazole, itraconazole, voriconazole,
amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes.
Antimicrob. Agents Chemother. 46:1581–1582.
35. Thomas, A. J., S. Shah, M. S. Mathews, and N. Chacko. 2008. Apophysomy-
ces elegans—renal mucormycosis in a healthy host: a case report from south
India. Indian J. Med. Microbiol. 26:269–271.
36. van Burik, J. A., R. S. Hare, H. F. Solomon, M. L. Corrado, and D. P.
Kontoyiannis. 2006. Posaconazole is effective as salvage therapy in zygomy-
cosis: a retrospective summary of 91 cases. Clin. Infect. Dis. 42:e61–e65.
37. Verweij, P. E., G. M. Gonzalez, N. P. Wiedrhold, C. Lass-Florl, P. Warn, M.
Heep, M. A. Ghannoum, and J. Guinea. 2009. In vitro antifungal activity of
isavuconazole against 345 mucorales isolates collected at study centers in
eight countries. J. Chemother. 21:272–281.
38. Wieden, M. A., K. K. Steinbronn, A. A. Padhye, L. Ajello, and F. W. Chan-
dler. 1985. Zygomycosis caused by Apophysomyces elegans. J. Clin. Microbiol.
22:522–526.
VOL. 48, 2010 EPIDEMIOLOGY OF A. ELEGANS 4585
 o
n
 M
ay 1, 2017 by RADBO
UD UNIVERSITEIT NIJM
EG
EN
http://jcm.asm.org/
D
ow
nloaded from
 
